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ABSTRACT 
Molecular initiating events (MIEs) can be boiled down to chemical interactions. Chemicals that 
interact must have intrinsic properties that allow them this behavior, be these stereochemical, 
electronic or otherwise. In an attempt to discover some of these chemical characteristics we have 
constructed structural alert-style structure activity relationships (SARs) to computationally 
predict MIEs. This work utilizes chemical informatics approaches, searching the ChEMBL 
database for molecules that bind to a number of pharmacologically important human toxicology 
targets, including G-protein coupled receptors (GPCRs), enzymes, ion channels, nuclear 
receptors, and transporters. By screening these compounds to find common 2D fragments, and 
combining this approach with a good understanding of the literature, bespoke 2D structural alerts 
have been written. These SARs form the beginning of a tool for screening novel chemicals to 
establish the kind of interactions they may be able to make in humans. These SARs have been 
run through an internal validation to test their quality and the results of this are also discussed. 
MIEs have proven to be difficult to find and characterize but we believe we have taken a key 
first step with this work. 
 
INTRODUCTION 
The molecular initiating event (MIE) has been defined as a key chemical event in toxicity 
leading to adverse outcomes through adverse outcome pathways (AOPs).
1,2
 With its basis 
strongly founded in chemistry, the MIE makes a good starting point for the development of in 
silico tools, such as structure activity relationships (SARs). In order for a chemical (or 
metabolite/breakdown product) to cause an effect via an MIE it must conform to specific 
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chemical characteristics: those which allow it to bind to a receptor, inhibit an enzyme, or modify 
a protein. An MIE is essentially a chemical interaction. The links between these chemical 
characteristics and the MIE will undoubtedly be stronger than links to a toxicological endpoint, 
which is much further down the pathway. 
The AOP framework for risk assessment brings together chemical and biological understanding 
in an attempt to develop predictive methods for human and environmental toxicology.
3,4
 AOPs 
span multiple levels of biological organization, and as such a large amount of knowledge is 
required to make an AOP risk assessment. This will consist of knowledge of the exposure of an 
organism to a chemical, followed by an understanding of how that chemical is absorbed, 
distributed, metabolized and excreted and hence how much of the chemical gets to the active 
site. Once the chemical reaches the active site how, and to what extent, does it bind to, or interact 
with, a target? How does this interaction lead to a disturbance of the biosystem within this 
organism and, finally, how does this disturbance leads to effects at a measurable, level of 
biological organization? This is indeed a large undertaking. However, the AOP provides a 
framework that, once these pieces are in place, can provide a genuine alternative to in vivo 
testing.
5–7
 
MIEs are already being used as gateways to the development of predictive tools and mechanistic 
understanding. The MIE has been used in quantitative structure activity relationship (QSAR) 
development
8
 and category formation and read across
9
 within in silico tools. Molecular 
modelling is also finding a use for the MIE, in research leading to an increase in mechanistic 
understanding of biological-chemical interactions.
10
 Once the potential for a compound to 
activate an MIE has been established, this can be linked to in vitro studies of downstream 
biomarkers associated with known AOPs, allowing risk assessment to be carried out. 
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The development, evaluation and current trends in SAR and QSAR research have been well 
reviewed.
11,12
 Despite advances in these powerful in silico techniques they are still treated with 
some suspicion in the toxicology community. Their role in toxicology risk assessment is 
generally confined to chemical screening.
2
 Anchoring SARs and QSARs at the MIE removes 
large amounts of biological complexity from the models, providing stronger links between 
chemical characteristics and the prediction of adverse outcomes. The construction of clear 
models with sound theoretical backing is of great importance, and these will illustrate the value 
of the technique. 
One such type of SAR in toxicity prediction relies on the use of structural fragments from within 
molecules to distinguish active compounds from inactive ones. One such approach has been used 
in the development of SAR “rules” for skin sensitization.
13
 Similar approaches are used within 
computational tools, such as Derek Nexus, a knowledge-based expert system for qualitative 
toxicity prediction based on chemical structure.
14
 The OECD QSAR toolbox 
(http://www.oecd.org/chemicalsafety/risk-assessment/theoecdqsartoolbox.htm) provides a 
further example of the use of chemical characteristics being linked to potential mechanism or 
mode of action.
15
 The use of structural alerts can be associated with MIEs in predictive 
toxicology and tools to make these predictions are already under development.
16,17
 
The aim of this work is to build a structural alert-style SAR approach to predict MIEs in silico. 
This study has been conducted with a number of pharmacologically important human targets for 
systemic toxicity drawn from a paper by Bowes in 2012
18
, and several targets of interest from 
our previous work.
1
 In particular the Bowes receptors are highlighted as pharmacologically 
important off-target interactions, often leading to the failure of new drug candidates in clinical 
trials.
18
 These receptors are also of importance in the development of ingredients for consumer 
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goods products as they could lead to damaging systemic toxicity outcomes. As important drug 
safety targets these receptors are also likely to have a good amount of biological in vitro data 
available for analysis and the construction of models, providing a further advantage. In addition 
to this these targets cover a wide variety of different biomolecules, and a good representation of 
biological space. As such these receptors provide a good starting point for the development of 
any in silico technique. These targets include G-protein coupled receptors (GPCRs), enzymes, 
ion channels, nuclear receptors and transporters (Table 1).  
These biological targets require MIEs to be described in a different way to the well-characterized 
skin sensitization alerts based on chemical reactivity,
19
 because binders are likely to sit in a 
sterically restricted receptor binding pockets or enzyme active sites and interact with the 
biomolecule through hydrogen bonds, or charge-charge and hydrophobic interactions. 
Fortunately structural and pharmacophore-style 2D fragments coded in SMILES and SMARTS 
can still describe these alerts well.  
2D fragment based approaches to SARs have several advantages. They are computationally 
simple, allowing the rapid assessment of a large number of chemicals without the use of a large 
amount of computational resources.  2D SARs are also mechanistically transparent, and can be 
easily interpretable as to what it is about a molecule that causes it to activate an MIE. Despite 
this they do have their limitations. For example, this strategy only locates common substructures 
in the training data when a relatively large common molecular scaffold is available. Some 
biological targets are promiscuous and only slight changes in the chemistry of binders results in a 
large change in biological activity, which is sometimes difficult to describe with a chemical 
fragment. These fragments also do not analyze the chemical characteristics of whole molecules, 
and so important pieces of information can be missed if they are just outside of the located 
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fragment. Finally using 2D substructures to model 3D environments is considered an incomplete 
way to predict biological activity. The shape and size of a molecule may play a bigger role in its 
ability to fit into, and bind to, a biological target than its chemical features, particularly if the 
target is a well-defined enzyme active site. This can only be assessed in 3D. 
One target may have more than one MIE. From a chemical perspective it is also true that one 
binding pocket may allow chemicals to bind to it through different interactions, and these may 
lead to a diversity of alerts. The alerts in this paper are for a specific “mode of binding” (MOB) 
and this term will be used in this study to avoid confusion. Without additional biological 
understanding, it is sometimes not clear if two alerts apply to the same MIE, or to different ones. 
MATERIALS AND METHODS 
Data Set. ChEMBL (https://www.ebi.ac.uk/chembl/, version 19, extracted November 2014) was 
used, containing more than a million annotated compounds, comprising more than twelve million 
bioactivities covering more than 10 000 targets, all abstracted from the primary scientific 
literature.
20
 Compounds with a confidence score of 8 or 9 and with reported activities 
(Ki/Kd/IC50/EC50) better than, or equal to, 10 µM against human protein targets were treated as 
positives and used for model generation. These cutoffs were chosen to provide chemicals with a 
pharmacologically-relevant activity at a specific, well-defined, human target. A cut-off of 10 µM 
will ensure that the compounds have a good degree of biological activity and represents a trade-
off between activity and dataset size. A confidence score of 8 represents the assignment of 
homologous single proteins, and 9 direct single protein interactions.
21
 These compounds are 
binders irrespective of agonistic and antagonistic activity. Non-binders were omitted from the 
generation of the models because of the small fraction of compounds found in ChEMBL with 
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reported activities below 10 µM. Only receptors with at least twenty active compounds were 
used to ensure enough information is available to construct appropriate in silico models. The data 
set for each target was split randomly into 75 % training set and a 25 % test set using a function 
in Pipeline Pilot,
22
 so internal validation could be provided. The data were uniquified to ensure 
no duplicate data corrupted results. This was performed on the molecular structure of each 
chemical based on their atomic connectivity, resulting in different tautomers, enantiomers and 
salts being treated as different data points. The training sets were then combined and uniquified 
to make an amalgamated training set, and the test sets were combined in an analogous fashion to 
make an amalgamated test set. These give a representation of ChEMBL chemical space. The 
amalgamated training set was used to provide fragments present across the whole set. It was not 
used in the development of models. The amalgamated test set was used in the internal validation. 
These compounds had unknown activity across each receptor but were used as anticipated 
negatives to give an idea of chemical space. This is done to overcome bias in the ChEMBL set 
towards positives, and allow model quality to be better assessed than through the use of 
sensitivity alone. In total 51 179 activities across 30 349 unique compounds and 45 human 
targets (Table 1) were extracted for model construction. 
Model Construction. The compound’s canonical SMILES were used to generate 2D fragment-
based structural alerts using custom scripting in Pipeline Pilot.
22
 Molecular fragments were 
identified based on matching atom types and charges between molecules. Partial aliphatic rings 
were allowed within fragments. The fragment size and frequency within the training set were 
altered to sample a diversity of potentially active fragments. The outputs were viewed and 
curated manually to identify key fragments which are associated with positive activity, rather 
than just being common among medicinal chemicals. Text based literature searches were 
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conducted using SciFinder to find information on targets that could aid in the construction of 
models. In some cases, crystal structures were found. In others, well-known molecules with 
precisely understood binding behavior were found and the structures of these compared to the 
found fragments. Based on the elucidated fragments, and understanding gained through the 
literature searches, structural alerts were coded as SMILES strings or SMARTS and models were 
constructed using a substructure filter. 
Internal Validation. Test sets were used to calculate sensitivity (SE) for each structural alert.  
 =

 + 
 
In order to provide a negative test set for each human receptor target the test set for the target of 
interest was subtracted from the amalgamated test set. As such every negative test set is not the 
same. This is to give an idea of chemical space, but the chemicals are untested against the target 
of interest and are treated as negatives only for the purpose of this analysis. This is done to 
provide analysis and get a confidence score for models. As such these results must be treated 
carefully, but should provide more guidance greater than sensitivity-only calculations. 
Specificity (SP) is calculated from these results.  
 =

 + 
 
Overall quality (Q) is calculated based on the total number of correct predictions.  
	 =
 + 
 +  +  + 
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To overcome the issue of having a larger negative test set than positive the Matthews correlation 
coefficient (MCC) was used;
23
 

 =
 ×  −  × 
( + )( + )( + )( + )
 
RESULTS AND DISCUSSION 
Amalgamated Set 
In the search for common 2D fragments in the ChEMBL dataset it is inevitable that some 
fragments will be found that are simply common among medicinal chemicals within ChEMBL. 
In order to take this into account, and to prevent models being built using fragments that are 
simply common across the entire dataset of all receptors, a bespoke model building process is 
used. The fragments are subjected to human analysis, and appropriate fragments selected, rather 
than simply using a computer to select all fragments. In addition to this, a dataset was 
constructed containing all compounds across all test sets analyzed in this study. This training set 
was uniquified, and then run through the same protocols used to generate 2D fragments for each 
receptor. This generated a number of fragments that are simply common among medicinal 
chemicals of this type, and so should not be considered indicative of any particular receptor-
ligand interaction, unless exceptionally high percentages of the training set include them. These 
are shown in Figure 1. 
As may have been expected, some fragments, including benzene rings, aliphatic amines, and 
short carbon chains are commonly present. 
Structural Alerts 
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Across the 45 human targets analyzed in this work, 126 structural alerts have been developed, 
and these are shown in Table 2. These structural alerts include those found using maximal 
common substructure searches using Pipeline Pilot, those found in typical ligands for the target, 
those identified in previously accepted pharmacophores, those identified in existing crystal 
structures, and combinations of these. Each alert is labelled in Table 2 to indicate its origin and 
pharmacophores, crystal structures and typical binders found in the literature are referenced. The 
SMILES and SMARTS that were coded for these structural alerts are provided in supporting 
information. Table 2 also provides the fraction of positives identified by each alert in the training 
set.  
Results for the internal validation of structural alerts are shown in Table 3. A total of 126 alerts 
have been produced across 45 human targets. In large part this has been successful, with 77 
models across 39 targets producing MCC values of greater than 0.2 (representing 60 % correct 
predictions for a balanced data set), 28 models across 21 targets giving MCC values greater than 
0.4 (70 % correct predictions for a balanced data set), and seven models across seven receptors 
scoring MCC values of greater than 0.6 (80 % correct predictions for a balanced data set) in 
internal validation. These results must be treated with a note of caution, however, as the 
remainder of the ChEMBL training set was used as a negative test set, meaning these compounds 
have not been confirmed as true negatives. Despite this, these results show that the structural 
alerts that have been developed do not tend to over-fire, and as such the results obtained by 
running a novel chemical through these structural alerts should be of benefit to a toxicologist 
wanting to be able to perform a pragmatic risk assessment when combined with other data, or 
identify targets of interest for further investigation.  
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This study has produced an average of just under three structural alerts (2.93) per target. It is 
notable that a number of targets have only one structural alert covering a large proportion of their 
active compounds (Dihydrofolate reductase, GAR transformylase, tyrosine-protein kinase, the 
glutamate (NMDA) receptor, the HERG channel, and the voltage gated K channel subunit 
Kv7.1). This suggests that these biological targets are quite specific in the compounds that they 
accept and hence there is less structural variability in their binders. Only two targets have more 
than five fragments, the adrenergic 2a receptor (6) and monoamine oxidase (7), indicating that 
these are more promiscuous receptors with more structurally varied binders. 
Combined Models 
2D structural alerts, such as those developed in this work, can be used in toxicity screening, as a 
hazard identification tool, or as a tool in risk assessment to support a decision on chemical safety. 
In each of these cases the structural alerts will be used in different ways. In hazard identification 
tools need to be calibrated to provide maximum safety; that is to minimize the number of false 
negatives at the expense of the number of false positives predicted. In risk assessment tools will 
be adjusted to provide maximum accuracy; to provide the best possible predictivity as measured 
by a metric such as MCC.  
To provide results on the structural alerts developed in this work for hazard identification, the 
structural alerts for each target were combined into a model requiring a molecule to contain any 
of the structural alerts to be predicted a positive. These models were tested against the positive 
test set for each target to provide a sensitivity value in each case. These results are shown in 
Table 4. This provides perspective on the proportion of binders likely to be predicted by these 
models, in a hazard assessment exercise. 45 models were tested and their sensitivity values 
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calculated. 29 models scored sensitivity values of 50% or more, 13 scored 75% or more and five 
scored 90% or more. These results provide a promising basis for the construction of a toxicity 
screening tool for hazard identification based on these structural alerts predicting MIEs. 2D 
structural alert methods such as this have an advantage in hazard assessment as they are 
computationally quick and inexpensive, and often hazard assessment requires the processing of 
large numbers of chemicals to screen out potentially toxic molecules at an early stage of 
compound development. 
Risk assessment for individual chemicals is very different to hazard identification, and as such 
requires a different approach. Small numbers of chemicals are assessed on a case-by-case basis 
to ensure their safety. This requires expert input and pragmatic decision making by an expert 
scientist, and as such a batch test of these structural alerts is not an appropriate way to assess 
their value. 2D structural alerts such as these may find use in this field, and if they do it is 
important that the expert takes into account the results from our study to make an informed 
decision as to whether a chemical is likely to bind to a given target or not. The statistical results 
for sensitivity, specificity, overall quality and MCC values provided in Table 2 give guidance as 
to which of the alerts are most predictive and which are likely to over-fire. Alerts with a high 
sensitivity and MCC are very predictive and should be most useful in risk assessment. Alerts 
with a low specificity are hitting a number of compounds that are not considered binders in 
ChEMBL, and as such will produce a large number of false positives in risk assessment.  
Further research will be required to expand our work to other key MIEs and improve it to the 
point where it can quantitatively predict the amount of a toxicant required at a target to exhibit a 
toxicological response. In addition to this a number of other tools will be required to accurately 
predict the amount of a toxicant that is able to reach the site of the MIE, and the biological 
Page 13 of 57
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 14
response that will result from the activation of the MIE, in order to represent a complete risk 
assessment. 
Biological Relevance 
The AOP Wiki represents the best current repository for AOP information, and as such a search 
was performed to identify AOPs which could result from the binding of a molecule to the targets 
examined in this work.
24
 The majority of the AOPs that may be associated with this work are 
currently under development (totaling 19 pathways) and the associated targets are listed below: 
• Acetylcholinesterase 
• Androgen Receptor 
• Cyclooxygenase (5 pathways) 
• Ether-a-go-go voltage gated potassium channel 
• Glucocorticoid Receptor (2 pathways) 
• Glutamate Receptor 
• Histamine H2 Receptor 
• Serotonin Transporter (2 pathways) 
• Sodium Channel (3 pathways) 
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This shows much promise for the future of AOP-based toxicology studies, as the AOP Wiki is 
currently in its infancy and will continue to grow over time, providing further scope for the 
identification of potentially toxic pathways using work such as this.  
One pathway from the AOP wiki is well developed for agonism of the androgen receptor leading 
to reproductive dysfunction in adult female fish. While this pathway is not based on human 
toxicology studies, with time the AOP Wiki will be able to provide such detailed pathways for 
human toxicity pathways. In addition to this there are a number of MIEs, KEs and AOPs that 
transcend species and as such this research may be relevant to human toxicology. In essence 
agonism at the androgen receptor leads to a decrease in the concentrations of the hormones 
gonadotropin, testosterone, estradiol and vitellogenin. A decrease in vitellogenin uptake leads to 
impaired development of oocytes, decreased spawning rates and a population decline. A graphic 
of this AOP is shown in Figure 2. 
Further information on clinical pathways that may be affected by the agonism or antagonism of 
the targets studied in this work is presented in the Bowes 2012 article.
18
 
CONCLUSIONS 
 
As toxicology moves away from animal based approaches and towards in silico and in vitro 
methods, further understanding and new tools are required. The MIE is the first KE in the AOP, 
the boundary between chemistry and biology where a chemical makes its first key interaction 
with the body. By understanding the chemical properties of existing receptor-binding chemicals 
we aim to be able to predict the MIEs of new molecules computationally. The focus of this work 
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was to utilize open source data to develop 2D structural alert-based SAR models for the 
prediction of MIEs associated with pharmacologically important human targets. 
We have produced a number of 2D SAR models in an attempt to describe the characteristic 
fragments that allow molecules to cause effects via MIEs. A total of 126 alerts across 45 human 
targets have been developed in this work. A number of these alerts performed well, with an 
emphasis on being able to combine alerts into models for individual targets which will have high 
levels of specificity and therefore will not over-fire. When the 45 combined models were tested, 
29 models scored sensitivity values of 50% or more, 13 scored 75% or more and five scored 90% 
or more, providing overall a good level of coverage. To prevent the models over-firing the whole 
ChEMBL data set was analyzed to provide fragments that are common in chemicals in this set, 
and as such should not be used as structural alerts. This information was used, along with 
existing pharmacophores, crystal structures and an understanding of typical binders found in the 
literature, to manually curate structural alerts provided by a maximal common substructure 
searches and develop structural alerts. This has resulted in a number of structural alerts with high 
specificity values: 95 of 126 alerts scored 95% or greater specificity values. 
Understanding of the chemical characteristics that govern receptor MIEs will be a key step in the 
development of AOP based tools for toxicity risk assessment. 2D fragment based approaches are 
not the only way to attempt to answer this complex problem, and a number of approaches will 
need to be combined to provide a quantitative risk assessment. In this first step we have begun to 
explore this area, with sights set on the development of in silico screening tools. We believe that 
these fragment alerts can provide useful information in compound development, regarding the 
potential toxic effects of lead chemical compounds, and provide a basis for exciting new 
developments in the understanding of receptor MIEs, and how they can be used in toxicology. 
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AA2aR, adenosine A2a receptor; AC, acetylcholinesterase; ADR, adrenergic receptor; AOP, 
adverse outcome pathway; AR, androgen receptor; CCKAR, cholecystokinin A receptor; COX, 
cyclooxygenase; CR, cannabinoid receptor; DHFR, dihydrofolate reductase; DR, dopamine 
receptor; DT, dopamine transporter; E2, estradiol; ER ET-A, endothelin receptor ET-A; GART, 
GAR transformylase; GPCR, G-protein coupled receptor; GR, glucocorticoid receptor; GRSZ1, 
glutamate receptor subunit zeta 1; GtH, gonadotropin hormone; HDAC 1, histone deacetylase 1; 
HERG; human ether-a-go-go related gene; HR, histamine receptor; LCK, tyrosin protein kinase; 
MAO A, monoamine oxidase A; MAR, muscarinic acetylcholine receptor; MCC, Matthews 
correlation coefficient; MIE, molecular initiating event; MOB, mode of binding; NMDA, N-
methyl-D-aspartate; NT, norepinephrine transporter; OR, opioid receptor; PDE, 
phosphoidesterase; Q, overall quality; (Q)SAR, (quantitative)structure activity relationship; 
SCV-A, sodium channel V subunit alpha; SE, sensitivity; SP, specificity; SR, serotonin receptor; 
ST, serotonin transporter; T, testosterone; TS, thymidylate synthase; VGKC Kv7.1, voltage gated 
K channel subunit Kv7.1; VTG, vitellogenin; VV1a, vasopressin V1a. 
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FIGURES 
 
Figure 1. 2D fragments common within the entire dataset for this study. Part 1A shows 
fragments larger than four chemical bonds present within 50 % or greater of the data set. Part 1B 
shows fragments larger than seven chemical bonds present within 30 % or greater of the data set. 
Part 1C shows fragments larger than 12 chemical bonds present within 10 % or greater of the 
data set. 
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Figure 2. AOP for androgen receptor agonism leading to reproductive dysfunction. The MIE is 
shown in green, KEs in orange and adverse outcomes in red as per the AOP Wiki template. 
Reduced GtH secretion in the hypothalamus/pituitary is shown in white as there is uncertainty as 
to the specific mechanism through which androgen receptor agonism elicits a negative feedback 
response at this key event. E2: estradiol, GtH: gonadotropin hormone, T: testosterone, VTG: 
vitellogenin. 
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TABLES 
Target 
 
 
Binders 
 
Binders 
Training 
Set 
Binders 
Test Set 
(positive) 
Test Set 
(negative) G-Protein Coupled Receptors 
Adenosine A2a Receptor 2960 2150 810 10820 
 
   
Alpha-1a Adrenergic Receptor 705 510 195 11435 
Alpha-2a Adrenergic Receptor 380 269 111 11519 
Beta-1 Adrenergic Receptor 694 505 189 11441 
Beta-2 Adrenergic Receptor 770 540 230 11400 
 
   
Cannabinoid CB1 Receptor 3738 2688 1050 10580 
Cannabinoid CB2 Receptor 3405 2435 970 10660 
 
   
Cholecystokinin Receptor A 255 177 78 11552 
 
   
Dopamine D1 Receptor 453 322 131 11499 
Dopamine D2 Receptor 2589 1831 758 10872 
 
   
Endothelin Receptor A 100 72 28 11602 
 
   
Histamine H1 Receptor 672 499 173 11457 
Histamine H2 Receptor 191 141 50 11580 
 
   
Muscarinic Acetylcholine Receptor M1 887 639 248 11382 
Muscarinic Acetylcholine Receptor M2 620 456 164 11466 
Muscarinic Acetylcholine Receptor M3 1067 772 295 11335 
 
   
Delta Opioid Receptor 2550 1657 893 10737 
Kappa Opioid Receptor 2347 1721 626 11004 
Mu Opioid Receptor 2793 2056 737 10893 
 
   
Serotonin 1A Receptor 1777 1273 504 11126 
Serotonin 1B Receptor 396 282 114 11516 
Serotonin 2A Receptor 1612 1162 450 11180 
Serotonin 2B Receptor 750 555 195 11435 
 
   
Vasopressin V1A Receptor 651 471 180 11450 
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Enzymes 
  
 
Acetylcholinesterase 1355 989 366 11264 
 
 
Cyclooxygenase 1 379 274 105 11525 
Cyclooxygenase 2 964 686 278 11352 
 
 
Dihydrofolate Reductase 404 294 110 11520 
 
 
GAR Transformylase 36 23 13 11617 
 
 
Histone Deacetylase 1 1202 882 320 11310 
 
 
Monoamine Oxidase A 533 382 151 11479 
 
 
Phosphodiesterase 3A 132 94 38 11592 
Phosphodiesterase 4D 385 267 118 11512 
 
 
Thymidylate Synthase 239 178 61 11569 
 
 
Tyrosine-Protein Kinase 568 414 154 11476 
 
 
Ion Channels 
   
   
Glutamate (NMDA) Receptor 25 18 7 11623 
    
Potassium Voltage Gated Channel KQT-like Member 1 295 215 80 11550 
 
Serotonin 3A Receptor 316 230 86 11544 
 
 
Sodium Channel V Subunit Alpha 153 111 42 11588 
 
 
Voltage Gated K Channel Subunit Kv7.1 28 21 7 11623 
 
 
Nuclear Receptors 
  
 
Androgen Receptor 1598 1186 412 11218 
 
  
Glucocorticoid Receptor 2201 1622 579 11051 
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Transporters 
  
 
Dopamine Transporter 1908 1414 494 11136 
 
 
Norepinephrine Transporter 2616 1923 693 10937 
 
 
Serotonin Transporter 3480 2578 902 10728 
 
Table 1. Pharmacological targets analyzed in this work. Data was extracted from ChEMBL 
version 19. The total test set in each case was 11 630 compounds. 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
 
 
  
G-Protein Coupled Receptors 
 
 
Adenosine A2a Receptor   
 
    
 
Alert AA2aR 1 - 2-Pyrimidine
 
S 
 
842/2150 
 
 
Alert AA2aR 2 - 4-Pyrimidine S,L
25,26
 
 
647/2150 
 
Alert AA2aR 3 - Adenine S,L
25,26
 
 
349/2150 
 
Alert AA2aR 4 - AA2aR Frag 1 S,L
27
 
 
364/2150 
 
 
Adrenergic Receptors   
 
    
Alpha Alert A-ADR 1 - Phenylpiperazine-like S,L 
 
207/758 
 
 
Alert A-ADR 2 - Tolazoline-like S,L
28–32
 7/758 
 
 
 
Alpha-1a Alert A-1aADR 1 - Phenylethanolamine-like L
29,33–36
 10/510 
 
Alert A-1aADR 2 - 1-Ethyl-4-phenylpiperazine-like S 
 
158/510 
 
 
 
Alpha-2a Alert A-2aADR 1 - CID 5145436 S 
 
55/269 
 
Alert A-2aADR 2 - CID 13001 S 
 
52/269 
 
Alert A-2aADR 3 - A2aADR Frag 2 S 
 
37/269 
 
Alert A-2aADR 4 - 4-Benzyl-1H-imidazole-like L
37
 
 
3/269 
 
Alert A-2aADR 5- Guanidine L
31,38
 
 
9/269 
 
Alert A-2aADR 6 - 2-(1-Hydroxyl ethyl)-2-imidazole S 
 
50/269 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
  
 
 
Beta Alert B-ADR 1 - 1-(Phenethylamino)propan-2-ol-like S 
 
383/774 
 
Alert B-ADR 2 - 2-(Ethylamino)-1-phenylethanol-like S 
 
509/774 
 
Alert B-ADR 3 - 1-(Ethylamino)-3-phenoxyl-2-                    
                            propanol-like 
S 
 
194/774 
  
Cannabinoid Receptor   
 
    
 
 
 
CB1 Alert CCB1R 1 - 2-Phenylpyrazole-like S 
 
391/2688 
 
Alert CCB1R 2 - 5-Phenyl-1H-pyrazole-like S 
 
286/2688 
 
Alert CCB1R 3 - Pyrazole-3-carboxamide S 
 
321/2688 
 
 
CB2 Alert CCB2R 1 - CCB2R Frag 1 S 
 
298/2435 
 
 
Alert CCB2R 2 - 1-(1-Ethyl-1H-pyrrol-3-yl)ethanone S 
 
217/2435 
 
 
CB1 & CB2 Alert CR 1 - Indole S 
 
489/3362 
 
 
Cholecystokinin A Receptor   
 
    
 
  
 
 
Alert CCKAR 1 - 2-Acetamido-N-methylacetamide       S,L
39–41
 72/177 
 
Alert CCKAR 2 - N-[2-(methylamino)ethyl]acetamide S,L
39–41
 159/177 
 
Alert CCKAR 3 - CID 9957635 S 
 
63/177 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
 
Dopamine Receptors   
 
    
 
  
D1 Alert DD1R 1 - Dihydrexine-like
 
 L
42
 
 
21/322 
 
Alert DD1R 2 - Benzazepine-like L
42
 
 
20/322 
 
Alert DD1R 3 - Benzazepine-like with aromatic L
42
 
 
19/322 
 
Alert DD1R 4 - CID 15288 S 
 
84/322 
 
 
D2 Alert DD2R 1 - Piperazine
 
 S 
 
1006/1831 
 
 
Alert DD2R 2 - 1,4 Dimethylpiperazine S 
 
1000/1831 
 
Alert DD2R 3 - Phenylpiperazine S 
 
727/1831 
 
 
Endothelin Receptor A   
 
    
 
 
 
 
Alert ER ET-A 1 - 5-Ethyl-1,3-benzodioxole S,L
43
 
 
23/72 
 
Alert ER ET-A 2 - N-Methylbenzenesulfonamide-like S 
 
53/72 
 
Alert ER ET-A 3 - Tryptamine S 
 
25/72 
 
Alert ER ET-A 4 - ER ET-A Frag 1-like S 
 
30/72 
 
Alert ER ET-A 5 - N-Methyl-2-biphenylsulfonamide-like S 
 
25/72 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
  
 
  
Histamine Receptors   
 
    
 
  
H1 Alert HH1R 1 - Doxepine-like S,X
44
 
 
58/444 
 
Alert HH1R 2 - 4-Phenoxypiperidine S 
 
66/444 
 
 
 
H2 Alert HH2R 1 - Imidazole S 
 
36/126  
 
Alert HH2R 2 - Guanidine S 
 
46/126 
 
Alert HH2R 4 - Indole S 
 
36/126 
 
 
Muscarinic Acetylcholine Receptors   
 
    
M1 and M2 Alert MAR 1 - Formanilide S,L
45,46
 238/844 
 
 
 
M2 and M3 Alert MAR 2 - N-Ethyl-N,N-dimethylpropanaminum S,L
 47,48
 316/915  
 
 
 
M3 Alert MAR 3 - Tetramethylamonium S,L
 47,48
 316/772  
 
 
 All Alert MAR 4 - MAR Pharmacophore X
49
 393/1236 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
   
 
  
Opioid Receptors   
 
    
 
 
 
 
Alert OR 1 - Morphine-like (4 or more)  X,P
50
 
 
164/1385 
 
Alert OR 1 - Morphine-like (3 or more)  X,P
50
 
 
459/1385 
 
 
Alert OR 2 - 1-Methyl-4-phenylpiperidine S 
 
668/1385 
 
 
Serotonin Receptors   
 
    
 
 
 
All Alert SR 1 - 3-Ethyl Indole S 
 
299/2633 
 
 
1A, 1B, 2A Alert SR 1a1b2a 1 - 1-Methyl-4-Phenylpiperazine-like S 
 
 
908/2377 
 
 
 
1A Alert SR 1a 1 - SR 1a Frag 2 S 
 
65/1208 
 
 
1B Alert SR 1b 1 - 2-Methyl-1,2-dihydroquinoline S 
 
116/282 
 
 
 
2B Alert SR 2b 1 - CID 15206310 S 
 
41/555 
 
Alert SR 2b 2 - SR 2b Frag 2 S 
 
31/555 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
   
 
  
Vasopressin V1a   
 
    
 
Alert VV1a 1 - VV1a Frag 1 S,L
51–53
 224/471 
 
 
Alert VV1a 2 - n-benzyl-n-ethylmethylamine S 
 
243/471 
 
Alert VV1a 3 - VV1a Frag 3 S,L
51–53
 187/471 
 
Alert VV1a 4 - VV1a Frag 4 S,L
51–53
 128/471 
 
 
Enzymes 
 
 
 
Acetylcholinesterase   
 
    
 
 
 
 
Alert AC 1a - Tacrine S,L
54
 
 
184/989 
 
Alert AC 1b - 4-Quinolinamine S,L
54
 
 
192/989 
 
Alert AC 1c - AC Frag 1 S,L
54
 
 
245/989 
 
Alert AC 1d - Dimethyl benzylamine S,L
54
 
 
395/989 
 
Alert AC 1e - Dimethyl benzylamine-like SMARTS S,L
54
 
 
401/989 
 
 
 
Cyclooxygenases   
 
    
 
 
 
 
Alert COX 1 - Sulfonated aromatic rings S 
 
392/816 
 
Alert COX 2 - Cinnamaldehyde-like S 
 
183/816 
 
Alert COX 3 - 5-Phenyl-1H-pyrazole-like S 
 
70/816 
Page 36 of 57
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 37
Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
 
 
Dihydrofolate Reductase   
 
    
 
 
 
 
Alert DHFR 1 (SMILES) - Diaminopyrimidine S,L
 55
,X
56
 145/237 
 
Alert DHFR 1 (SMARTS) - Diaminopyrimidine-like
 
 S,L
 55
,X
56
 158/237 
 
 
 
GAR Transformylase   
 
    
 
 
 
 
Alert GART 1 - N-Acetyl-DL-glutamic acid S 
 
23/23 
 
 
 
Histone Deacetylase 1   
 
    
 
  
 
Alert HDAC 1 1 - Hydroxamic acids S,L
57,58
 
 
416/882 
 
Alert HDAC 1 2a - Benzamide S,L
57,58
 
 
271/882 
 
Alert HDAC 1 2b - Benzamide-like SMARTS S,L
57,58
 
 
316/882 
 
Alert HDAC 1 2c - Acetanilide S,L
57,58
 
 
355/882 
 
Alert HDAC 1 2d - Acetanilide-like SMARTS S,L
57,58
 
 
372/882 
 
Alert HDAC 1 2e - Benzanilide S,L
57,58
 
 
165/882 
 
Alert HDAC 1 2f - Benzanilide-like SMARTS S,L
57,58
 
 
198/882 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
   
 
  
Monoamine Oxidase   
 
    
 
 
 
 
Alert MAO A 1 - 3-Phenyl-2-oxazolidone L
59,60
 
 
12/382 
 
Alert MAO A 2a - 4-Methylphenol S 
 
99/382 
 
Alert MAO A 2b - 3-Methylphenol S 
 
80/382 
 
Alert MAO A 2c - Methyl-3,4-diphenol S 
 
10/382 
 
Alert MAO A 3a - Aminomethiazole S 
 
58/382 
 
Alert MAO A 3b - 4-Phenyl-1,3-thiazole-2-amine S 
 
57/382 
 
Alert MAO A 3c - CID 7958070 S 
 
54/382 
 
 
 
Phosphodiesterases   
 
    
 
 
 
3A Alert PDE 3A 1 - PDE 3A Frag 2 S,X
61
 
 
18/94 
 
Alert PDE 3A 2a - PDE Frag 3 S,X
61
 
 
11/94 
 
Alert PDE 3A 2b - PDE Frag 3-like SMARTS S,X
61
 
 
15/94 
 
Alert PDE 3A 3 - PDE 3A Frag 4 S 
 
34/94 
 
Alert PDE 3A 4 - Veratrol-like S,X
61
 
 
36/94 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
   
 
  
4D Alert PDE 4D 1 - Homoveratrol-like S,X
61
 
 
83/267 
 
 
Alert PDE 4D 2 - 8-Isopropyl-1H-purine Frag S 
 
24/267 
 
Alert PDE 4D 3 - PDE 4D Frag 3 S 
 
74/267 
 
 
Thymidylate Synthase   
 
    
 
Alert TS 1 - N-Acetyl-DL-glutamic acid S,L
62
 
 
21/145 
 
 
Alert TS 2 - Pyrimidine L
62
 
 
8/145 
 
Alert TS 3 - Uracil L
62
 
 
2/145 
 
 
Tyrosine Protein Kinase   
 
    
 
  
 
Alert LCK 1 - Pyrimidine-like S,L
63
 
 
212/383 
 
 
Ion Channels 
 
 
 
Glutamate (NMDA) Receptor   
 
    
 
 
 
 
Alerts GRSZ1 1 - GRSZ1 Frag 1 S 
 
18/18 
 
 
 
 
   
 
  
Page 39 of 57
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 40
Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
   
 
  
Potassium Voltage Gated Channel Subunit H Member 2    
 
    
 
 
 
 
Alert HERG 1a - Flex Aromatic Amine 1-5 S,P
64–67
 167/215 
 
Alert HERG 1b - Flex Aromatic Amine 2-5 S,P
64–67
 147/215 
 
 
 
Serotonin 3A Receptor   
 
    
 
  
 
Alert S3AR 1 - S3AR Frag 1 S,L
68
 
 
47/229 
 
Alert S3AR 2 - 1-[2-(Phenylsulfanyl)phenyl]piperazine S,L
69
 
 
27/229 
 
 
 
Sodium Channel V Subunit alpha   
 
    
 
 
 
 
Alert SCV-A 1a - Pyrimidine-like aromatic S 
 
49/111 
 
Alert SCV-A 1b - Pyrimidine-like wildcard S 
 
49/111 
 
Alert SCV-A 2 - 4-(4-Piperidineyloxy)pyrimidine S 
 
30/111 
 
Alert SCV-A 3 - SCV Frag 1 S 
 
28/111 
 
Alert SCV-A 4 - N-(2-Phenylethyl)acetamide S 
 
25/111 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
   
 
  
Voltage Gated K Channel Sub Unit Kv7.1   
 
    
 
 
 
 
Alert VGKC Kv7.1 1 - VGKV Kv7.1 Frag 1 S 
 
21/21 
 
 
 
Nuclear Receptors 
 
 
 
Androgen Receptor   
 
    
 
Alert AR 1a - Benzonitrile S,L
70
 
 
294/764 
 
 
Alert AR 1b - Nitrobenzene S,L
70–72
 73/764 
 
Alert AR 1c - Quinolone S,L
70
 
 
128/764 
 
 
Glucocorticoid Receptor   
 
    
 
Alert GR 1a - GR Frag 1 S,L
73–75
 228/1232 
 
 
Alert GR 1b - tert-Butylcyclohexane
 
 S,L
73–75
 166/1232 
 
Alert GR 1c - GR Frag 4 S,L
73–75
 201/1232 
 
Alert GR 1d - GR Frag 5 S,L
73–75
 198/1232 
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Receptor MIE 
 
Origin 
  
Training Set Hits Alerts 
   
 
  
Transporters 
 
 
 
Dopamine Transporter   
 
    
 
 
 
 
Alert DT 1 - 3-Phenyl-8-azabicyclo[3.2.1]octane S,L
76,77
 
 
147/1159 
 
Alert DT 2 - Diphenylmethane-like S,L
78
 
 
268/1159 
 
 
Norepinephrine Transporter   
 
    
 
 
 
 
Alert NT 1a - Cocaine-like 1 S,L
79
 
 
60/1573 
 
Alert NT 1b - Cocaine-like 2 S,L
79
 
 
61/1573 
 
Alert NT 1c - Cocaine-like 3 S,L
79
 
 
106/1573 
 
Alert NT 1d - Cocaine-like 4 S,L
79
 
 
117/1573 
 
Alert NT 2 - Amphetamines-like S,L
79
 
 
1164/1573 
 
 
 
Serotonin Transporter   
 
    
 
Alert ST 1 - 3-Ethyl-indole S,L
80
 
 
175/2166 
 
 
Alert ST 2 - DMEA S,L
80
 
 
1438/2166 
 
Alert ST 3 - Benzyloxybenzene S,L
80
 
 
172/2166 
 
Alert ST 4 - Diphenylmethane S,L
80
 
 
192/2166 
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Table 2. Structural alerts developed for each receptor with the fraction of hits within each training set shown. Alerts are labelled based 
on their origin, S for fragments identified by maximal common substructure search using Pipeline Pilot, L for fragments found in 
typical ligands found in the literature, P for fragments based on an existing pharmacophore and X for fragments derived from an 
existing crystal structure. Alerts are shown pictorially as they have been coded in SMARTS or SMILES, with aromatic heavy atoms 
depicted as (a), aliphatic heavy atoms depicted as (A), and wildcard atoms (any heavy atom) depicted as (*).
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
 G-Protein Coupled Receptors 
 
Adenosine A2a Receptor                     
 
Alert AA2aR 1 - 2-Aminopyrimidine 
 
319 491 10591 229 
 
39.4 97.9 93.8 0.448 
 
Alert AA2aR 2 - 4-Aminopyrimidine 
 
251 559 10441 379 
 
31.0 96.5 91.9 0.309 
 
Alert AA2aR 1 OR 2 
 
505 305 10343 477 
 
62.3 95.6 93.3 0.530 
 
Alerts AA2aR 1 AND 2 
 
65 745 10689 131 
 
8.0 98.8 92.5 0.135 
 
Alert AA2aR 3 - Adenine 
 
137 673 10771 49 
 
16.9 99.5 93.8 0.334 
 
Alert AA2aR 4 - AA2aR Frag 1 
 
155 655 10820 0 
 
19.1 100.0 94.4 0.425 
 Adrenergic Receptors                     
Alpha-1a/-2a Alert A-ADR 1 - Phenylpiperazine-like 
 
69 234 10318 1009 
 
22.8 91.1 89.3 0.076 
 
Alert A-ADR 2 - Tolazoline-like 
 
6 297 11326 1 
 
2.0 100.0 97.4 0.128 
 Alpha-1a Alert A-1aADR 1 - Phenylethanolamine-like 
 
6 189 11136 299 
 
3.1 97.4 95.8 0.004 
 
Alert A-1aADR 2 - 1-Ethyl-4-phenylpiperazine-like 54 141 10705 730 
 
27.7 93.6 92.5 0.109 
 Alpha-2a Alert A-2aADR 1 - CID 5145436 
 
24 86 11513 7 
 
21.8 99.9 99.2 0.408 
 
Alert A-2aADR 2 - CID 13001 
 
22 88 11507 13 
 
20.0 99.9 99.1 0.351 
 
Alert A-2aADR 1 OR 2 
 
24 86 11505 15 
 
21.8 99.9 99.1 0.363 
 
Alert A-2aADR 3 - A2aADR Frag 2 
 
6 104 11484 36 
 
5.5 99.7 98.8 0.083 
 
Alert A-2aADR 4 - 4-Benzyl-1H-imidazole-like 
 
3 107 11515 5 
 
2.7 100.0 99.0 0.099 
 
Alert A-2aADR 5- Guanidine 
 
10 100 11342 178 
 
9.1 98.5 97.6 0.058 
 
Alert A-2aADR 6 - 2-(1-Hydroxyl ethyl)-2-immidazole 22 88 11515 5 
 
20.0 100.0 99.2 0.401 
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
           
Beta Alert B-ADR 1 - 1-(Phenethylamino)propan-2-ol-like 168 203 11154 105 
 
45.3 99.1 97.4 0.515 
 
Alert B-ADR 2 - 2-(Ethylamino)-1-phenylethanol-like 242 129 11207 52 
 
65.2 99.5 98.4 0.725 
 
Alert B-ADR 3 - 1-(Ethylamino)-3-phenoxyl-2-propanol-like 102 269 11178 81 
 
27.5 99.3 97.0 0.378 
 
Alert B-ADR 1 OR 2 OR 3 
 
350 21 11025 234 
 
94.3 97.9 97.8 0.742 
 Cannabinoid Receptor                     
CB1 Alert CCB1R 1 - 2-Phenylpyrazole-like 
 
170 880 10296 284 
 
16.2 97.3 90.0 0.200 
 
Alert CCB1R 2 - 5-Phenyl-1H-pyrazole-like 
 
117 933 10445 135 
 
11.1 98.7 90.8 0.194 
 
Alert CCB1R 3 - Pyrazole-3-carboxamide 
 
148 902 10533 47 
 
14.1 99.6 91.8 0.305 
 
Alert CCB1R 1 OR 2 
 
178 872 10210 370 
 
17.0 96.5 89.3 0.182 
 
Alerts CCB1R 1 AND 2 
 
109 941 10531 49 
 
10.4 99.5 91.5 0.246 
 
Alerts CCB1R 1, 2 AND 3 
 
86 964 10576 4 
 
8.2 100.0 91.7 0.267 
 CB2 Alert CCB2R 1 - CCB2R Frag 1 
 
111 859 10612 48 
 
11.4 99.5 92.2 0.262 
 
Alert CCB2R 2 - 1-(1-Ethyl-1H-pyrrol-3-yl)ethanone 96 874 10621 39 
 
9.9 99.6 92.1 0.246 
 CB1 & CB2 Alert CR 1 - Indole 
 
207 1594 9043 786 
 
11.5 92.0 79.5 0.045 
 Cholecystokinin A Receptor                     
 
Alert CCKAR 1 - 2-Acetamido-N-methylacetamide 35 43 11209 343 
 
44.9 97.0 96.7 0.193 
 
Alert CCKAR 2 - N-[2-(methylamino)ethyl]acetamide 76 2 10595 957 
 
97.4 91.7 91.8 0.256 
 
Alert CCKAR 3 - CID 9957635 
 
30 48 11552 0 
 
38.5 100.0 99.6 0.619 
             
            
            
            
            
            
Page 47 of 57
ACS Paragon Plus Environment
Chemical Research in Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 48
Receptor MIE   TP FN TN FP   SE SP Q MCC 
            
Dopamine Receptor                     
D1 Alert DD1R 1 - Dihydrexine-like 
 
10 121 11447 52 
 
7.6 99.5 98.5 0.104 
 
Alert DD1R 2 - Benzazepine-like 
 
9 122 11454 45 
 
6.9 99.6 98.6 0.101 
 
Alert DD1R 3 - Benzazepine-like with aromatic 
 
9 122 11499 0 
 
6.9 100.0 99.0 0.261 
 
Alert DD1R 4 - CID 15288 
 
32 99 11472 27 
 
24.4 99.8 98.9 0.359 
 D2 Alert DD2R 1 - Piperazine 
 
417 341 9678 1194 
 
55.0 89.0 86.8 0.315 
 
Alert DD2R 2 - 1,4 Dimethylpiperazine 
 
416 342 9928 944 
 
54.9 91.3 88.9 0.355 
 
Alert DD2R 3 - Phenylpiperazine 
 
321 437 10285 587 
 
42.3 94.6 91.2 0.340 
 Endothelin Receptor A                     
 
Alert ER ET-A 1 - 5-Ethyl-1,3-benzodioxole 
 
3 25 11573 29 
 
10.7 99.8 99.5 0.098 
 
Alert ER ET-A 2 - N-Methylbenzenesulfonamide-like 18 10 11107 495 
 
64.3 95.7 95.7 0.143 
 
Alert ER ET-A 3 - Tryptamine 
 
8 20 11340 262 
 
28.6 97.7 97.6 0.086 
 
Alert ER ET-A 4 - ER ET-A Frag 1-like 
 
14 14 11602 0 
 
50.0 100.0 99.9 0.707 
 
Alert ER ET-A 5 - N-Methyl-2-biphenylsulfonamide-like 13 15 11585 17 
 
46.4 99.9 99.7 0.447 
 
Alert ER ET-A 4 OR 5 
 
14 14 11585 17 
 
50.0 99.9 99.7 0.474 
 Histamine Receptors                     
H1 Alert HH1R 1 - Doxepine-like 
 
24 134 11106 366 
 
15.2 96.8 95.7 0.077 
 
Alert HH1R 2 - 4-Phenoxypiperidine 
 
21 137 11412 60 
 
13.3 99.5 98.3 0.178 
 H2 Alert HH2R 1 - Imidazole 
 
15 33 10635 947 
 
31.3 91.8 91.6 0.054 
 
Alert HH2R 2 - Guanidine 
 
14 34 11408 174 
 
29.2 98.5 98.2 0.141 
 
Alert HH2R 4 - Indole 
 
20 28 10609 973 
 
41.7 91.6 91.4 0.076 
 
Alert HH2R 1, 2 OR 4 
 
38 10 9558 2024 
 
79.2 82.5 82.5 0.104 
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
            
Muscarinic Acetylcholine Receptors                     
M1 and M2 Alert MAR 1 - Formanilide 
 
102 270 9782 1476 
 
27.4 86.9 85.0 0.074 
 M2 and M3 Alert MAR 2 - N-Ethyl-N,N-dimethylpropanaminum 129 282 11175 44 
 
31.4 99.6 97.2 0.473 
 M3 Alert MAR 3 - Tetramethylamonium 
 
118 177 11245 90 
 
40.0 99.2 97.7 0.465 
 All Alert MAR 4 - MAR Pharmacophore 
 
198 394 10541 497 
 
33.4 95.5 92.3 0.268 
 Opioid Receptors                     
 
Alert OR 1 - Morphine-like (4 or more) 
 
164 1221 10238 7 
 
11.8 99.9 89.4 0.317 
 
Alert OR 1 - Morphine-like (3 or more) 
 
459 926 9867 378 
 
33.1 96.3 88.8 0.369 
 
Alert OR 2 - 1-Methyl-4-phenylpiperidine 
 
668 717 9957 288 
 
48.2 97.2 91.4 0.536 
 Serotonin Receptors                     
All Alert SR 1 - 3-Ethyl Indole 
 
125 1041 9946 518 
 
10.7 95.0 86.6 0.076 
 1A, 1B, 2A Alert SR 1a1b2a 1 - 1-Methyl-4-Phenylpiperazine-like 397 621 10011 601 
 
39.0 94.3 89.5 0.336 
 1A Alert SR 1a 1 - SR 1a Frag 2 
 
33 471 11118 8 
 
6.5 99.9 95.9 0.222 
 1B Alert SR 1b 1 - 2-Methyl-1,2-dihydroquinoline 
 
46 68 11323 193 
 
40.4 98.3 97.8 0.269 
 2B Alert SR 2b 1 - CID 15206310 
 
15 180 11425 10 
 
7.7 99.9 98.4 0.211 
 
Alert SR 2b 2 - SR 2b Frag 2 
 
8 187 11435 0 
 
4.1 100.0 98.4 0.201 
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
            
Vasopressin V1a                     
 
Alert VV1a 1 - VV1a Frag 1 
 
70 110 10811 639 
 
38.9 94.4 93.6 0.172 
 
Alert VV1a 2 - n-benzyl-n-ethylmethylamine 
 
90 90 9928 1522 
 
50.0 86.7 86.1 0.131 
 
Alert VV1a 3 - VV1a Frag 3 
 
66 114 11144 306 
 
36.7 97.3 96.4 0.238 
 
Alert VV1a 4 - VV1a Frag 4 
 
41 139 11372 78 
 
22.8 99.3 98.1 0.271 
 Enzymes 
 
Acetylcholinesterase                     
 
Alert AC 1a - Tacrine 
 
74 292 11261 3 
 
20.2 100.0 97.5 0.435 
 
Alert AC 1b - 4-Quinolinamine 
 
77 289 11233 31 
 
21.0 99.7 97.2 0.378 
 
Alert AC 1c - AC Frag 1 
 
97 269 11261 3 
 
26.5 100.0 97.7 0.501 
 
Alert AC 1d - Dimethyl benzylamine 
 
127 239 9596 1668 
 
34.7 85.2 83.6 0.096 
 
Alert AC 1e - Dimethyl benzylamine-like SMARTS 142 224 9710 1554 
 
38.8 86.2 84.7 0.124 
 Cyclooxygenases                     
 
Alert COX 1 - Sulfonated aromatic rings 
 
187 168 10567 708 
 
52.7 93.7 92.5 0.299 
 
Alert COX 2 - Cinnamaldehyde-like 
 
58 297 10912 363 
 
16.3 96.8 94.3 0.121 
 
Alert COX 3 - 5-Phenyl-1H-pyrazole-like 
 
34 321 11057 218 
 
9.6 98.1 95.4 0.090 
 
Alerts COX 1 OR 2 
 
226 129 10218 1057 
 
63.7 90.6 89.8 0.298 
 Dihydrofolate Reductase                     
 
Alert DHFR 1 (SMILES) - Diaminopyrimidine 
 
63 37 11397 133 
 
63.0 98.8 98.5 0.444 
 
Alert DHFR 1 (SMARTS) - Diaminopyrimidine-like 65 35 10535 995 
 
65.0 91.4 91.1 0.181 
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
            
GAR Transformylase                     
 
Alert GART 1 - N-Acetyl-DL-glutamic acid 
 
10 3 11592 25 
 
76.9 99.8 99.8 0.468 
 Histone Deacetylase 1                     
 
Alert HDAC 1 1 - Hydroxamic acids 
 
147 173 11296 14 
 
45.9 99.9 98.4 0.641 
 
Alert HDAC 1 2a - Benzamide 
 
83 237 10066 1244 
 
25.9 89.0 87.3 0.077 
 
Alert HDAC 1 2b - Benzamide-like SMARTS 
 
100 220 9846 1464 
 
31.3 87.1 85.5 0.088 
 
Alert HDAC 1 2c - Acetanilide 
 
127 193 10380 930 
 
39.7 91.8 90.3 0.179 
 
Alert HDAC 1 2d - Acetanilide-like SMARTS 
 
135 185 9654 1656 
 
42.2 85.4 84.2 0.125 
 
Alert HDAC 1 2e - Benanilide 
 
61 259 11173 137 
 
19.1 98.8 96.6 0.226 
 
Alert HDAC 1 2f - Benanilide-like SMARTS 
 
73 247 11135 175 
 
22.8 98.5 96.4 0.241 
 Monoamine Oxidase                     
 
Alert MAO A 1 - 3-Phenyl-2-oxazolidone 
 
6 145 11477 2 
 
4.0 100.0 98.7 0.171 
 
Alert MAO A 2a - 4-Methylphenol 
 
37 114 9431 2048 
 
24.5 82.2 81.4 0.020 
 
Alert MAO A 2b - 3-Methylphenol 
 
35 116 9698 1781 
 
23.2 84.5 83.7 0.024 
 
Alert MAO A 2c - Methyl-3,4-diphenol 
 
3 148 10901 578 
 
2.0 95.0 93.8 -0.016 
 
Alert MAO A 3a - Aminomethaziole 
 
26 125 11415 64 
 
17.2 99.4 98.4 0.215 
 
Alert MAO A 3b - 4-Phenyl-1,3-thiazole-2-amine 24 127 11452 27 
 
15.9 99.8 98.7 0.268 
 
Alert MAO A 3c - CID 7958070 
 
24 127 11479 0 
 
15.9 100.0 98.9 0.396 
 Phosphodiesterases                     
3A Alert PDE 3A 1 - PDE 3A Frag 2 
 
9 29 11592 0 
 
23.7 100.0 99.8 0.486 
 
Alert PDE 3A 2a - PDE Frag 3 
 
6 32 11592 0 
 
15.8 100.0 99.7 0.397 
 
Alert PDE 3A 2b - PDE Frag 3-like SMARTS 
 
7 31 11592 0 
 
18.4 100.0 99.7 0.429 
 
Alert PDE 3A 3 - PDE 3A Frag 4 
 
14 24 11574 18 
 
36.8 99.8 99.6 0.400 
 
Alert PDE 3A 4 - Veratrol-like 
 
13 25 11139 453 
 
34.2 96.1 95.9 0.088 
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
            
4D Alert PDE 4D 1 - Homoveratrol-like 
 
47 71 11311 201 
 
39.8 98.3 97.7 0.264 
 
Alert PDE 4D 2 - 8-Isopropyl-1H-purine Frag 
 
19 99 11512 0 
 
16.1 100.0 99.1 0.400 
 
Alert PDE 4D 3 - PDE 4D Frag 3 
 
50 68 10932 580 
 
42.4 95.0 94.4 0.165 
 Thymidylate Synthase                     
 
Alert TS 1 - N-Acetyl-DL-glutamic acid 
 
13 41 11554 22 
 
24.1 99.8 99.5 0.296 
 
Alert TS 2 - Pyrimidine 
 
2 52 11423 153 
 
3.7 98.7 98.2 0.014 
 
Alert TS 1 AND 2 
 
1 53 11576 0 
 
1.9 100.0 99.5 0.136 
 
Alert TS 3 - Uracil 
 
3 51 11537 39 
 
5.6 99.7 99.2 0.059 
 Tyrosine Protein Kinase                     
 
Alert LCK 1 - Pyrimidine-like 
 
78 71 10494 987 
 
52.3 91.4 90.9 0.171 
 Ion Channels 
 
Glutamate (NMDA) Receptor                     
 
Alerts GRSZ1 1 - GRSZ1 Frag 1 
 
7 0 11623 0 
 
100.0 100.0 100.0 1.000 
 Potassium Voltage Gated Channel Subunit H Member 2                     
 
Alert HERG 1a - Flex Aromatic Amine 1-5 
 
60 20 5493 6057 
 
75.0 47.6 47.7 0.037 
 
Alert HERG 1b - Flex Aromatic Amine 2-5 
 
53 27 6046 5504 
 
66.3 52.3 52.4 0.031 
 Serotonin 3A Receptor                     
 
Alert S3AR 1 - S3AR Frag 1 
 
12 74 11544 0 
 
14.0 100.0 99.4 0.372 
 
Alert S3AR 2 - 1-[2-(Phenylsulfanyl)phenyl]piperazine 7 79 11533 11 
 
8.1 99.9 99.2 0.175 
 
Alert S3AR 1 or 2 
 
19 67 11533 11 
 
22.1 99.9 99.3 0.372 
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
            
Sodium Channel V Subunit alpha                     
 
Alert SCA-A 1a - Pyrimidine-like aromatic 
 
24 18 10466 1122 
 
57.1 90.3 90.2 0.096 
 
Alert SCA-A 1b - Pyrimidine-like wildcard 
 
24 18 10466 1122 
 
57.1 90.3 90.2 0.096 
 
Alert SCA-A 2 - 4-(4-Piperidineyloxy)pyrimidine 9 33 11588 0 
 
21.4 100.0 99.7 0.462 
 
Alert SCA-A 3 - SCV Frag 1 
 
8 34 11588 0 
 
19.0 100.0 99.7 0.436 
 
Alert SCA-A 4 - N-(2-Phenylethyl)acetamide 
 
11 31 11133 455 
 
26.2 96.1 95.8 0.068 
 Voltage Gated K Channel Subunit Kv7.1                     
 
Alert VGKC Kv7.1 1 - VGKV Kv7.1 Frag 1 
 
7 0 11618 5 
 
100.0 100.0 100.0 0.764 
 Nuclear Receptors 
 
Androgen Receptor                     
 
Alert AR 1a - Benzonitrile 
 
132 205 11075 218 
 
39.2 98.1 96.4 0.366 
 
Alert AR 1b - Nitrobenzene 
 
39 298 11191 102 
 
11.6 99.1 96.6 0.164 
 
Alert AR 1c - Quinolone 
 
59 278 11247 46 
 
17.5 99.6 97.2 0.303 
 
Alert AR 1a, 1b OR 1c 
 
230 107 10927 366 
 
68.2 96.8 95.9 0.495 
 Glucocorticoid Receptor                     
 
Alert GR 1a - GR Frag 1 
 
74 378 11159 19 
 
16.4 99.8 96.6 0.352 
 
Alert GR 1b - tert-Butylcyclohexane 
 
55 397 11145 33 
 
12.2 99.7 96.3 0.265 
 
Alert GR 1c - GR Frag 4 
 
68 384 11168 10 
 
15.0 99.9 96.6 0.354 
 
Alert GR 1d - GR Frag 5 
 
68 384 11023 155 
 
15.0 98.6 95.4 0.192 
 
Alerts GR 1a OR 1c OR 1d 
 
76 376 11005 173 
 
16.8 98.5 95.3 0.204 
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Receptor MIE   TP FN TN FP   SE SP Q MCC 
            
Transporters 
 
Dopamine Transporter                     
 
Alert DT 1 - 3-Phenyl-8-azabicyclo[3.2.1]octane 63 372 11136 59 
 
14.5 99.5 96.3 0.260 
 
Alert DT 2 - Diphenylmethane-like 
 
101 334 9902 1293 
 
23.2 88.5 86.0 0.068 
 Norepinephrine Transporter                     
 
Alert NT 1a - Cocaine-like 1 
 
15 623 10961 31 
 
2.4 99.7 94.4 0.075 
 
Alert NT 1b - Cocaine-like 2 
 
16 622 10960 32 
 
2.5 99.7 94.4 0.079 
 
Alert NT 1c - Cocaine-like 3 
 
33 605 10903 89 
 
5.2 99.2 94.0 0.098 
 
Alert NT 1d - Cocaine-like 4 
 
37 601 10789 203 
 
5.8 98.2 93.1 0.063 
 
Alert NT 2 - Amphetamines-like 
 
486 152 4158 6834 
 
76.2 37.8 39.9 0.066 
 Serotonin Transporter                     
 
Alert ST 1 - 3-Ethyl-indole 
 
78 749 10238 565 
 
9.4 94.8 88.7 0.047 
 
Alert ST 2 - DMEA 
 
68 759 4256 6547 
 
8.2 39.4 37.2 -0.272 
 
Alert ST 3 - Benzyloxybenzene 
 
81 746 10635 168 
 
9.8 98.4 92.1 0.146 
 
Alert ST 4 - Diphenylmethane 
 
227 600 10258 545 
 
27.4 95.0 90.2 0.231 
 
Table 3. Results for test sets of each receptor with the remaining test sets acting as negatives. TP=True Positive, FN=False Negative, 
TN=True Negative, FP=False Positive, SE=Sensitivity, SP=Specificity, Q=Overall Quality, MCC=Matthews Correlation Coefficient.  
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Target     TP FN   SE 
 GPCRs             
 Adenosine A2a Receptor Alert 1, 2 3 OR 4 
 
505 305 
 
62.35 
 
   
Alpha-1a Adrenergic Receptor Alert 1, 2 OR 3 
 
57 138 
 
29.23 
Alpha-2a Adrenergic Receptor Alert 1, 2, 3, 4, 5 OR 6 
 
43 67 
 
39.09 
Beta-1 Adrenergic Receptor Alert 1, 2 OR 3 (beta alerts) 
 
182 7 
 
96.30 
Beta-2 Adrenergic Receptor Alert 1, 2 OR 3 (beta alerts) 
 
215 15 
 
93.48 
 
   
Cannabinoid CB1 Receptor Alert 1, 2 OR 3 
 
179 871 
 
17.05 
Cannabinoid CB2 Receptor Alert 1 OR 2 
 
207 763 
 
21.34 
 
   
Cholecystokinin Receptor A Alert 1, 2 OR 3 
 
76 2 
 
97.44 
 
   
Dopamine D1 Receptor Alert 1, 2, 3 OR 4 
 
45 86 
 
34.35 
Dopamine D2 Receptor Alert 1, 2 OR 3 
 
417 341 
 
55.01 
 
   
Endothelin Receptor A Alert 1, 2, 3, 4 OR 5 
 
25 3 
 
89.29 
 
   
Histamine H1 Receptor Alert 1 OR 2 
 
45 113 
 
28.48 
Histamine H2 Receptor Alert 1, 2 OR 4 
 
38 10 
 
79.17 
 
   
Muscarinic Acetylcholine Receptor M1 Alert 1 OR 4 
 
109 139 
 
43.95 
Muscarinic Acetylcholine Receptor M2 Alert 1, 2 OR 4 
 
74 90 
 
45.12 
Muscarinic Acetylcholine Receptor M3 Alert 2, 3 OR 4 
 
128 167 
 
43.39 
 
   
Delta Opioid Receptor Alert 1 (3 or more) OR 2 
 
268 241 
 
52.65 
Kappa Opioid Receptor Alert 1 (3 or more) OR 2 
 
286 271 
 
51.35 
Mu Opioid Receptor Alert 1 (3 or more) OR 2 
 
353 306 
 
53.57 
 
   
Serotonin 1A Receptor 
Alert SR1, SR1a1b2a1 OR 
SR1a1  
313 191 
 62.10 
Serotonin 1B Receptor 
Alert SR1, SR1a1b2a1 OR 
SR1b1  
98 16 
 85.96 
Serotonin 2A Receptor Alert SR1 OR SR1a1b2a1 
 
140 310 
 
31.11 
Serotonin 2B Receptor Alert SR1, SR2b1 OR SR2b2 
 
37 158 
 
18.97 
 
   
Vasopressin V1A Receptor Alert 1, 2, 3 OR 4 
 
133 47 
 
73.89 
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Target     TP FN   SE 
       
Enzymes             
 
 
Acetylcholinesterase Alert 1a, 1b, 1c, 1d, OR 1e 
 
244 122 
 
66.67 
 
 
Cyclooxygenase 1 Alert 1, 2 OR 3 
 
45 60 
 
42.86 
Cyclooxygenase 2 Alert 1, 2 OR 3 
 
197 81 
 
70.86 
 
 
Dihydrofolate Reductase Alert 1 (SMARTS) 
 
65 35 
 
65.00 
 
 
GAR Transformylase Alert 1 
 
10 3 
 
76.92 
 
 
Histone Deacetylase 1 Alert 1, 2b, 2d OR 2f 
 
244 76 
 
76.25 
 
 
Monoamine Oxidase A Alert 1, 2a, 2b, 2c, 3a, 3b OR 3c 
 
77 74 
 
50.99 
 
 
Phosphodiesterase 3A Alert 1, 2b, 3 OR 4 
 
27 11 
 
71.05 
Phosphodiesterase 4D Alert 1, 2 OR 3 
 
78 40 
 
66.10 
 
 
Thymidylate Synthase Alert 1, 2 OR 3 
 
17 37 
 
31.48 
 
 
Tyrosine-Protein Kinase Alert 1 
 
78 71 
 
52.35 
 
 
 
Ion Channels             
 
   
Glutamate (NMDA) Receptor Alert 1 
 
7 0 
 
100.00 
      
Potassium Voltage Gated Channel KQT 1 Alert 1a 
 
60 20 
 
75.00 
    
Serotonin 3A Receptor Alert 1 OR 2 
 
19 67 
 
22.09 
 
 
Sodium Channel V Subunit Alpha Alert 1b, 2, 3 OR 4 
 
28 14 
 
66.67 
 
 
Voltage Gated K Channel Subunit Kv7.1 Alert 1 
 
7 0 
 
100.00 
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Target     TP FN   SE 
 
Nuclear Receptors             
 
 
Androgen Receptor Alert 1a, 1b OR 1c 
 
230 107 
 
68.25 
 
  
Glucocorticoid Receptor Alert 1a, 1b, 1c OR 1d 
 
76 376 
 
16.81 
    
  
Transporters             
 
 
Dopamine Transporter Alert 1 OR 2 
 
164 271 
 
37.70 
 
 
Norepinephrine Transporter Alert 1a, 1b, 1c, 1d OR 2 
 
490 148 
 
76.80 
 
 
Serotonin Transporter Alert 1, 2, 3 OR 4 
 
637 190 
 
77.03 
 
Table 4. Results for models of combined structural alerts for each receptor. TP=True Positive, 
FN=False Negative, SE=Sensitivity. 
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